[en] BACKGROUND: Risks associated with transfusion of allogeneic blood have prompted development of methods to avoid or reduce blood transfusions. New oxygen-carrying compounds such as diaspirin cross-linked hemoglobin (DCLHb) could enable more patients to avoid allogeneic blood transfusion. METHODS: The efficacy, safety, hemodynamic effects, and plasma persistence of DCLHb were investigated in a randomized, active-control, single-blind, multicenter study in post-cardiac bypass surgery patients. Of 1,956 screened patients, 209 were determined to require a blood transfusion and met the inclusion criteria during the 24-h post-cardiac bypass period. These patients were randomized to receive up to three 250-ml infusions of DCLHb (n = 104) or three units of packed erythrocytes (pRBCs; n = 105). Further transfusions of pRBCs or whole blood were permitted, if indicated. Primary efficacy end points were the avoidance of blood transfusion through hospital discharge or 7 days postsurgery, whichever came first, and a reduction in the number of units of pRBCs transfused during this same time period. Various laboratory, physiologic, and hemodynamic parameters were monitored to define the safety and pharmacologic effect of DCLHb in this patient population. RESULTS: During the period from the end of cardiopulmonary bypass surgery through postoperative day 7 or hospital discharge, 20 of 104 (19%) DCLHb recipients did not receive a transfusion of pRBCs compared with 100% of control patients (P < 0.05). The overall number of pRBCs administered during the 7-day postoperative period was not significantly different. Mortality was similar between the DCLHb (6 of 104 patients) and the control (8 of 105 patients) groups. Hypertension, jaundice/hyperbilirubinemia, increased serum glutamic oxalo-acetic transaminase, abnormal urine, and hematuria were reported more frequently in the DCLHb group, and there was one case of renal failure in each group. The hemodynamic effects of DCLHb included a consistent and slightly greater increase in systemic and pulmonary vascular resistance with associated increases in systemic and pulmonary arterial pressures compared with pRBC. Cardiac output values decreased more in the DCLHb group patients after the first administration than the control group patients. At 24 h postinfusion, the plasma hemoglobin level was less than one half the maximal level for any amount of DCLHb infused. CONCLUSIONS: Administration of DCLHb allowed a significant number (19%) of cardiac surgery patients to avoid exposure to erythrocytes postoperatively.
Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EP IV, Petersen LR: Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995; 333:1721-5
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685-90
Klein HG: Allogeneic transfusion risks in the surgical patient. AmJ Surg 1995; 170:21.S-6.S
Edna TH, Bjerkeset T: Association between blood transfusion and infection in injured patients. J Trauma 1992; 33:659-61
Gottlieb T: Hazards of bacterial contamination of blood products. Anaesth Intensive Care 1993; 21:20-3
Rosengart TK, Helm RE, DeBois WJ, Garcia N, Krieger KH, Isom OW: Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah's Witness patients: Implications for a "bloodless" surgical technique. J Am Coll Surg 1997; 184: 618-29
Azari M, Catarello K, Burhop K, Camacho T, Ebeling A, Estep T, Guzder S, Krause K, Marshall T, Rohn K, Sarajari R: Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb) for viral inactivation - effect of crosslinking Art Cells Blood Subs Immobil Biotech 1997; 25:521-6
Estep TN, Bechel MK, Miller TJ, Bagdasarian A: Virus inactivation in hemoglobin by heat, Blood substitutes. Edited by Chang TMS. New York, Marcel Dekker, 1989, pp 129-34
Birnbaum ML, Lipman J, Garrioch M, Daily E, Przybelski R: Diaspirin cross-linked hemoglobin (DCLHb) vs. blood in acutely anemic patients. Intensive Care Med 1997; 23(suppl 1):S85
Malcolm DS, Hamilton I, Schultz S, Cole F, Burhop K: Characterization of the hemodynamic response to intravenous diaspirin cross-linked hemoglobin solution in rats. Art Cells Blood Subs Immobil Biotech 1994; 22:91-107
Cohn SM, Farrell TJ: Diaspirin cross-linked hemoglobin resuscitation of hemorrhage: Comparison of a blood substitute with hypertonic saline and isotonic saline. J Trauma 1995; 39(2):210-7
Sharma AC, Singh G, Gulati A: Role of NO mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats. Am J Physiol 1995; 265(38):1379-88
Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA: Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution (DCLHb™). Crit Care Med 1996; 24:1993-2000
Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ: Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am J Kidney Dis 1995; 26:918-23
Garrioch MR, Larbuisson R, Brichant JF, Lamy M, Daily E, Przybelski R: The hemodynamic effects of diaspirin cross-linked hemoglobin (DCLHb) in the operative setting. Crit Care Med 1996; 24:A39
Rhea G, Bodenham AR, Mallik A, Daily EK, Przybelski RJ: Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit Care Med 1997; 25:1480-8
Powell CC, Schultz SC, Bums DG, Drucker WR, Malcolm DS: Resuscitation with diaspirin-cross-linked hemoglobin (DCLHb) restores subcutaneous oxygen tension as well as blood in rats. Surgical Forum 1993; 44:40-2
Przybelski RJ, Malcolm DS, Burris DG, Winslow RM: Cross-linked hemoglobin solution as a resuscitative fluid after hemorrhage in the rat. J Lab Clin Med 1992; 117:143-51
Chatterjee R, Welty EV, Walder RY, Pruitt SL, Rogers PH, Arnone A, Walder JA: Isolation and characterization of a new hemoglobin derivate cross-linked between the · chains (lysine 99 . 1 lysine 99 . 2). J Biol Chem 1986; 261:9929-37
Przybelski RJ, Daily EK: The pressor/perfusion effect of diaspirin cross-linked hemoglobin (DCLHb), Yearbook of Intensive Care and Emergency Medicine. Edited by Vincent JL. Heidelberg, Springer-Verlag, 1994, pp 252-63
Stover EP, Siegel LC, Parks R, Levin J, Body SC, Maddi R, D'Ambra MN, Mangano DT, Spiess BD: Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines. ANESTHESIOLOGY 1998; 88:327-33
Spence RK for the Blood Management Practice Guidelines Conference: Surgical red blood cell transfusion practice policies. Am J Surg 1995; 170(6A):3.S-15.S
Wedgewood JJ, Thomas JG: Perioperative haemoglobin: An overview of current opinion regarding the acceptable level of haemoglobin in the peri-operative period. EurJ Anaesthesiol 1996; 13:316-24
Goodnough LT, Despotis GJ, Hogue CW, Ferguson TB: On the need for improved transfusion indicators in cardiac surgery. Ann Thorac Surg 1995; 60:473-80
Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E, The Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New Engl J Med 1999; 340: 409-17
Carson JL, Spence RK, Poses RM, Bonavita G: Severity of anaemia and operative mortality and morbidity. Lancet 1988; 2:727-29
Viele MK, Weiskopf RB, Fisher D: Recombinant human hemoglobin does not affect renal function in humans: Analysis of safety and pharmacokinetics. ANESTHESIOLOGY 1997; 86:848-58
Hughes GS, Antal EJ, Locker PK, Francom SF, Adams EJ, Jacobs EE: Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 1996; 24:756-64
Kasper SM, Walter M, Grüne F, Bischoff A, Erasmi H, Buzello W: Effects of hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1996; 83:921-7
Sharma AC, Singh G, Gulati A: Role of NO mechanism in cardiovascular effects of diaspirin crosslinked hemoglobin in anesthetized rats. AmJ Physiol 1995; 269:H1379-488
Schultz SC, Grady B, Cole F, Hamilton I, Burhop K, Malcolm DS: A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 1993; 122:301-8
Gulati A, Rebello S: Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin. J Lab Clin Med 1994; 124:125-33
Teisseire B, Ropars C, Villereal M-C, Nicolau C: Long-term physiological effects of enhanced O2 release by inositol hexaphosphate-loaded erythrocytes. Proc Natl Acad Sci USA 1987; 84:6894-8